Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 15/3/2021
SIETES contiene 93212 citas

 
 
 1 a 20 de 41 siguiente >>
Presentar resultados
Seleccionar todas
1.Tiene citas relacionadas Cita con resumen
Eunjung Cha A. Monthly shot could be the ‘next revolution’ in HIV therapy, replacing daily pills. The Washington Post 2017:1. [Ref.ID 101921]
2.Enlace a cita originalTiene citas relacionadas Cita con resumen
Feuerstein A. STAT Plus: Strong results for a new HIV drug will be a big boost to Gilead Sciences. STAT 2017:24 de julio. [Ref.ID 101919]
3. Cita con resumen
Anónimo. Ibalizumab shows promising results treating multi-drug-resistant HIV. DIA Daily 2016:4. [Ref.ID 100869]
4. Cita con resumen
Stanaway JD, Flaxman AD, Naghavi M, Fitzmaurice C, Vos T, Abubakar I, Abu-Raddad LJ, Assadi R, Bhala N, Cowie B, Forouzanfour MH, Groeger J, Hanafiah KM, Jacobsen KH, James SL, MacLachlan J, Malekzadeh R, Martin NK, Mokdad AA, Mokdad AH, Murray CJL, Plass D, Rana S, Rein DB, Richardus JH, Sanabria J, Saylan M, Shahraz S, So S, Vlassov VV, Weiderpass E, Wiersma ST, Younis M, Yu C, El Sayed Zaki M, Cooke GS. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013. Lancet 2016;388:1081-8. [Ref.ID 100744]
5. Cita con resumen
de Bruin M, Viechtbauer W, Schaalma HP, Kok G, Abraham C, Hospers HJ. Standard care impact on effects of highly active antiretroviral therapy adherence interventions. A meta-analysis of randomized controlled trials. Arch Intern Med 2010;170:240-50. [Ref.ID 87849]
6.
Macroft A, Phillips AN, Gatell J, Ledergerber B, Fisher M, Clumeck N, Losso M, Lazzarín A, Fatkenheuer G, Lundgren JD, for the EuroSIDA Study Group. Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppresion who are taking combination antiretroviral therapy: an observational cohort study. Lancet 2007;370:407-13. [Ref.ID 80860]
7.Tiene citas relacionadas Cita con resumen
Madruga J, Berger D, McMurchie M, Suter F, Banhegyi D, Ruxrungtham K, Norris D, Lefebvre E, de Béthune MP, Tomaka F, De Pauw M, Vangeneugden T, Spinosa-Guzmán S, on behalf of the TITAN study group. Efficacy and safety of darunavir-ritonavir compared with that of lopinavir-ritonavir at 48 weeks in treatment-experienced, HIV-infected patients in TITAN: a randomised controlled phase III trial. Lancet 2007;370:49-58. [Ref.ID 80495]
8.Tiene citas relacionadas Cita con resumen
Lazzarín A, Campbell T, Clotet B, Johnson M, Katlama C, Moll A, Towner W, Trottier B, Peeters M, Vingerhoets J, de Smedt G, Baeten B, Beets G, Sinha R, Woodfall B, on behalf of the DUET-2 study group. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370:39-48. [Ref.ID 80494]
9.Tiene citas relacionadas Cita con resumen
Madruga J, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, Mills A, Pialoux G, Wilkin T, Peeters M, Vingerhoets J, de Smedt G, Leopold L, Trefiglio R, Woodfall B, on behalf of the DUET-1 study group. Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial. Lancet 2007;370:29-38. [Ref.ID 80493]
10.Tiene citas relacionadas Cita con resumen
Hirschel B, Perneger T. No patient left behind - better treatments for resistant HIV infection. Lancet 2007;370:3-5. [Ref.ID 80485]
11.Tiene citas relacionadas
Rodrigo Gonzalo-de-Liria C. La cara menos conocida del sida: la infección en los niños. Med Clin (Barc) 2007;128:52-4. [Ref.ID 79017]
12.Tiene citas relacionadas Cita con resumen
Resino S, Bellón JM, León JA, Resino R, Muñoz-Fernández MA, y Grupo Español de Infección Pediátrica VIH. Carga viral plasmática en niños infectados por el virus de la inmunodeficiencia humana que reciben tratamiento antirretroviral de gran actividad. Med Clin (Barc) 2007;128:49-51. [Ref.ID 79016]
13. Cita con resumen
The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006;355:2283-96. [Ref.ID 78629]
14. Cita con resumen
Filippi J, Roger P-M, Schneider SM, Durant J, Breittmayer J-P, Benzaken S, Bernard A, Dellamonica P, Hébuterne X, for the Groupe d'Etude Niçois Polyvalent en Infectiologie (GENPI). Infliximab and human immunodeficiency virus infection: viral load reduction and CD4+ T-cell loss related to apoptosis. Arch Intern Med 2006;166:1783-4. [Ref.ID 78160]
15.
Zink MC, Uhrlaub J, DeWitt J, Voelker T, Bullock B, Mankowski J, Tarwater PM, Clements J, Barber S. Neuroprotective and anti-human immunodeficiency virus activity of minocycline. JAMA 2005;293:2003-11. [Ref.ID 73556]
16.Tiene citas relacionadas
Taha TE, Kumwenda NI, Hoover DR, Fiscus SA, Kafulafula G, Nkhoma C, Nour S, Chen S, Liomba G, Miotti PG, Broadhead BL. Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting. A randomized controlled trial. JAMA 2004;292:202-9. [Ref.ID 70703]
17.Tiene citas relacionadas Cita con resumen
Gallant JE, Stazewski S, Pozniak A, DeJesus E, Suleiman JMAH, Miller MD, Coakley DF, Lu B, Toole JJ, Cheng AK, for the 903 Study Group. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients. A 3-yer randomized trial. JAMA 2004;292:191-201. [Ref.ID 70702]
19.Tiene citas relacionadas
Schooley RT. Starting highly active antiretroviral therapy for HIV infection: is it WIHS to wait?. Ann Intern Med 2004;24:305-6. [Ref.ID 69268]
20.Tiene citas relacionadas
Anastos K, Barrón Y, Cohen MH, Greenblatt RM, Minkoff H, Young M, Gange SJ. The prognostic importance of changes in CD4+ cell count and HIV-1 RNA level in women after initiating highly active antiretroviral therapy. Ann Intern Med 2004;24:256-64. [Ref.ID 69266]
Seleccionar todas
 
 1 a 20 de 41 siguiente >>